Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,178.00    -4.00 (-0.18%)
Bid:
2,192.00
Ask:
2,220.00
Spread: 28.00 (1.277%)
Market Cap: £1.45b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Senior Management Changes

4 Jan 2012 07:00

RNS Number : 9387U
Genus PLC
04 January 2012
 



 

For immediate release 4 January 2012

 

 

 

 

 

 

 

GENUS plc

("Genus" or "the Company")

 

Senior Management Changes

 

Genus, a leading global animal genetics company, announces two senior management changes within the Group.

 

Firstly, Genus is delighted to announce that Catherine Glickman will join the Company as Group Human Resources (HR) Director on January 5th 2012. Catherine will be leading the Group's talent management strategy as well as taking responsibility for engaging, equipping and investing in Genus employees to help the Group deliver its ambitious plans for growth. Catherine will become a member of the Genus Executive Leadership Team and will report directly to Karim Bitar, Chief Executive Officer.

 

Until recently, Catherine was the Head of HR at Tesco, one of the five largest global retailers with over 500,000 employees in 14 countries. During her 20 years at Tesco she was instrumental in developing the HR strategy that helped drive the retailer's strong growth and international expansion in recent years. Overall, she has over 25 years' experience in HR, within Tesco and beyond.

 

Secondly, Denny Funk Ph.D, the Company's Chief Scientific Officer, has also joined the Genus Executive Leadership Team. Dr. Funk will report directly to Karim Bitar, Chief Executive, and will have full responsibility for the Company's research & development (R&D) programme. This will ensure that R&D has a key and highly visible role as Genus pursues its ambitious plans for the future. Dr. Denny Funk was an Associate Professor at the University of Wisconsin-Madison before joining Genus in 1995.

 

Separately, Ian Biggs, formerly Head of Global Product and Business Strategy, has stepped down from his role to pursue other opportunities outside Genus. His primary responsibilities will be assumed by Dr. Denny Funk.

 

Karim Bitar, Chief Executive, commented:

 

 "I am delighted to announce the appointment of such a high calibre and experienced individual as Catherine to the role of Group HR Director. Catherine has been attracted and inspired by the Group's ambitious plans and is as enthusiastic as I am about the opportunities ahead. She will play a major role as she helps shape our talent management strategy."

 

"I would like thank Ian for the contribution he has made to Genus over the years and we wish him all the best for the future. Lastly, I am delighted that Denny has taken overall responsibility for R&D and I look forward to working with him closely as we ensure R&D plays a clear and consistent part in helping Genus meet evolving customer and market needs."

 

 

 

 

 

For further information please contact:

 

Genus plc Tel: 01256 345970

Karim Bitar, Chief Executive

John Worby, Finance Director

 

Buchanan Tel: 0207 466 5000

Charles Ryland, Suzanne Brocks, Catherine Breen

www.buchanan.uk.com 

 

 

This announcement is available on the Genus website, www.genusplc.com

 

 

About Genus

 

Genus creates advances to animal breeding through biotechnology and sells added value products for livestock farming and food producers. Its non-genetically modified organism technology is applicable across all livestock species but is only commercialised by Genus in the bovine and porcine farming sectors.

 

Genus' worldwide sales are made in seventy countries under the trademarks "ABS" (dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production. Customers' animals produce offspring with greater production efficiency, milk and meat output and quality, and use these to supply the global dairy and meat supply chain.

 

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global production and distribution network.

 

With headquarters in Basingstoke, England, Genus companies operate in thirty countries on six continents, with research laboratories located in Madison, Wisconsin, USA

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBJMRTMBJMBLT
Date   Source Headline
13th May 202612:32 pmRNSDirector/PDMR Shareholding
1st May 20269:20 amRNSTotal Voting Rights
13th Apr 20265:59 pmRNSDirector/PDMR Shareholding
1st Apr 20269:40 amRNSDirector/PDMR Shareholding
10th Mar 20263:56 pmRNSNotification of Major Holdings
10th Mar 20263:56 pmRNSNotification of Major Holdings
4th Mar 202610:33 amRNSDirector/PDMR Shareholding
4th Mar 202610:08 amRNSDirector Declaration
27th Feb 202612:48 pmRNSDirector/PDMR Shareholding
26th Feb 20267:00 amRNSInterim Results
2nd Feb 202612:39 pmRNSBlock Listing Return
2nd Feb 202611:21 amRNSTotal Voting Rights
2nd Feb 20267:00 amRNSSuccessful formation of Chinese porcine JV
23rd Jan 20265:23 pmRNSPRP Regulatory Progress – Canada
16th Jan 20267:00 amRNSHalf Year Trading Update – Ahead of expectations
27th Nov 20257:00 amRNSDirector/PDMR Shareholding
19th Nov 202512:12 pmRNSResults of AGM
19th Nov 20257:00 amRNSNon-Executive Director Appointments
19th Nov 20257:00 amRNSAGM Trading Update
3rd Nov 202510:56 amRNSTotal Voting Rights
14th Oct 20254:02 pmRNSNotification of Major Holdings
10th Oct 20257:00 amRNSNotice of AGM
1st Oct 20259:47 amRNSTotal Voting Rights
25th Sep 20254:49 pmRNSDirector/PDMR Shareholding
24th Sep 202511:35 amRNSDirector/PDMR Shareholding
19th Sep 20252:39 pmRNSDirector/PDMR Shareholding
17th Sep 202512:14 pmRNSDirector/PDMR Shareholding
11th Sep 202512:20 pmRNSDirector/PDMR Shareholding
8th Sep 20254:05 pmRNSAdditional Listing
4th Sep 20257:00 amRNSPreliminary results
4th Sep 20257:00 amRNSAccelerated Chinese porcine JV formation
28th Aug 20254:57 pmRNSNotification of Major Holdings
19th Aug 20253:03 pmRNSNotification of Major Holdings
19th Aug 20257:00 amRNSNotification of Major Holdings
6th Aug 202510:51 amBUSHolding(s) in Company
4th Aug 202511:14 amRNSNotification of Major Holdings
1st Aug 202510:10 amRNSBlock Listing Six Monthly Return
1st Aug 202510:05 amRNSTotal Voting Rights
15th Jul 20257:00 amRNSFY25 Trading Update
9th May 20259:25 amRNSAppointment of Financial Adviser & joint Broker
1st May 20252:28 pmRNSTotal Voting Rights
30th Apr 20257:00 amRNSPRRS Resistant Pig – FDA Approval
25th Apr 20254:30 pmRNSNotification of Major Holdings
25th Apr 20254:28 pmRNSNotification of Major Holdings
2nd Apr 20255:08 pmRNSDirector/PDMR Shareholding
2nd Apr 20253:43 pmRNSNotification of Major Holdings
13th Mar 20257:00 amRNSAppointment of Chief Financial Officer Designate
3rd Mar 202511:32 amRNSTotal Voting Rights
28th Feb 20251:30 pmRNSDirector/PDMR Shareholding
27th Feb 20257:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.